MIW815 + PDR001
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumors and Lymphomas
Conditions
Solid Tumors and Lymphomas
Trial Timeline
Sep 8, 2017 → Dec 18, 2020
NCT ID
NCT03172936About MIW815 + PDR001
MIW815 + PDR001 is a phase 1 stage product being developed by Novartis for Solid Tumors and Lymphomas. The current trial status is terminated. This product is registered under clinical trial identifier NCT03172936. Target conditions include Solid Tumors and Lymphomas.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03172936 | Phase 1 | Terminated |
Competing Products
20 competing products in Solid Tumors and Lymphomas